<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutr J</journal-id><journal-id journal-id-type="iso-abbrev">Nutr J</journal-id><journal-title-group><journal-title>Nutrition Journal</journal-title></journal-title-group><issn pub-type="epub">1475-2891</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22824168</article-id><article-id pub-id-type="pmc">3439338</article-id><article-id pub-id-type="publisher-id">1475-2891-11-52</article-id><article-id pub-id-type="doi">10.1186/1475-2891-11-52</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Report</subject></subj-group></article-categories><title-group><article-title>L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="A1"><name><surname>Kraft</surname><given-names>Matthias</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>matthias.kraft@uni-greifswald.de</email></contrib><contrib contrib-type="author" equal-contrib="yes" id="A2"><name><surname>Kraft</surname><given-names>Kathleen</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>kathleen.kraft@uni-greifswald.de</email></contrib><contrib contrib-type="author" id="A3"><name><surname>G&#x000e4;rtner</surname><given-names>Simone</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>simone.gaertner@uni-greifswald.de</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Mayerle</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>julia.mayerle@uni-greifswald.de</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Simon</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>peter.simon@uni-greifswald.de</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Weber</surname><given-names>Eckhard</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>eckhard.weber@uni-greifswald.de</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Sch&#x000fc;tte</surname><given-names>Kerstin</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>kerstin.schuette@med.ovgu.de</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Stieler</surname><given-names>Jens</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>Jens.Stieler@charite.de</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Koula-Jenik</surname><given-names>Heide</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>heidejenik@web.de</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Holzhauer</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>dr.med.holzhauer@veramed.de</email></contrib><contrib contrib-type="author" id="A11"><name><surname>Gr&#x000f6;ber</surname><given-names>Uwe</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>uwegroeber@gmx.net</email></contrib><contrib contrib-type="author" id="A12"><name><surname>Engel</surname><given-names>Georg</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>engelg@uni-greifswald.de</email></contrib><contrib contrib-type="author" id="A13"><name><surname>M&#x000fc;ller</surname><given-names>Cornelia</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>cornelia.mueller@uni-greifswald.de</email></contrib><contrib contrib-type="author" id="A14"><name><surname>Feng</surname><given-names>You-Shan</given-names></name><xref ref-type="aff" rid="I9">9</xref><email>you-shan.feng@uni-greifswald.de</email></contrib><contrib contrib-type="author" id="A15"><name><surname>Aghdassi</surname><given-names>Ali</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>aghdassi@uni-greifswald.de</email></contrib><contrib contrib-type="author" id="A16"><name><surname>Nitsche</surname><given-names>Claudia</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>claudia.nitsche@uni-greifswald.de</email></contrib><contrib contrib-type="author" id="A17"><name><surname>Malfertheiner</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>peter.malfertheiner@med.ovgu.de</email></contrib><contrib contrib-type="author" id="A18"><name><surname>Patrzyk</surname><given-names>Maciej</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>patrzyk@uni-greifswald.de</email></contrib><contrib contrib-type="author" id="A19"><name><surname>Kohlmann</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="I9">9</xref><email>kohlmann@uni-greifswald.de</email></contrib><contrib contrib-type="author" corresp="yes" id="A20"><name><surname>Lerch</surname><given-names>Markus M</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>lerch@uni-greifswald.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Medicine A, University Medicine Greifswald, Friedrich L&#x000f6;ffler Stra&#x000df;e 23a, Greifswald, 17475, Germany</aff><aff id="I2"><label>2</label>Department for Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University Magdeburg, Magdeburg, Germany</aff><aff id="I3"><label>3</label>Charit&#x000e9; Universitaetsmedizin Berlin, Campus Virchow-Clinic, Medical Clinic Hematology/Oncology, Berlin, Germany</aff><aff id="I4"><label>4</label>Veramed Clinic, Brannenburg, Germany</aff><aff id="I5"><label>5</label>Academy of Micronutrient Medicine, Essen, Germany</aff><aff id="I6"><label>6</label>University Pharmacy, University Medicine Greifswald, Greifswald, Germany</aff><aff id="I7"><label>7</label>Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany</aff><aff id="I8"><label>8</label>Department of Surgery, University Medicine Greifswald, Greifswald, Germany</aff><aff id="I9"><label>9</label>Institute of Community Medicine, University Medicine of Greifswald, Greifswald, Germany</aff><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>23</day><month>7</month><year>2012</year></pub-date><volume>11</volume><fpage>52</fpage><lpage>52</lpage><history><date date-type="received"><day>16</day><month>2</month><year>2012</year></date><date date-type="accepted"><day>23</day><month>7</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2012 Kraft et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Kraft et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.nutritionj.com/content/11/1/52"/><abstract><sec><title>Background</title><p>Cachexia, a &#x0003e;10% loss of body-weight, is one factor determining the poor prognosis of pancreatic cancer. Deficiency of L-Carnitine has been proposed to cause cancer cachexia.</p></sec><sec><title>Findings</title><p>We screened 152 and enrolled 72 patients suffering from advanced pancreatic cancer in a prospective, multi-centre, placebo-controlled, randomized and double-blinded trial to receive oral L-Carnitine (4&#x02009;g) or placebo for 12&#x02009;weeks. At entry patients reported a mean weight loss of 12&#x02009;&#x000b1;&#x02009;2,5 (SEM) kg. During treatment body-mass-index increased by 3,4&#x02009;&#x000b1;&#x02009;1,4% under L-Carnitine and decreased (&#x02212;1,5&#x02009;&#x000b1;&#x02009;1,4%) in controls (p&#x02009;&#x0003c;&#x02009;0,05). Moreover, nutritional status (body cell mass, body fat) and quality-of-life parameters improved under L-Carnitine. There was a trend towards an increased overall survival in the L-Carnitine group (median 519&#x02009;&#x000b1;&#x02009;50 d versus 399&#x02009;&#x000b1;&#x02009;43 d, not significant) and towards a reduced hospital-stay (36&#x02009;&#x000b1;&#x02009;4d versus 41&#x02009;&#x000b1;&#x02009;9d,n.s.).</p></sec><sec><title>Conclusion</title><p>While these data are preliminary and need confirmation they indicate that patients with pancreatic cancer may have a clinically relevant benefit from the inexpensive and well tolerated oral supplementation of L-Carnitine.</p></sec></abstract><kwd-group><kwd>Pancreatic adenocarcinoma</kwd><kwd>L-Carnitine</kwd><kwd>Quality of life</kwd><kwd>Survival</kwd><kwd>Cancer cachexia</kwd><kwd>Fatique syndrome</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Adenocarcinoma of the pancreas is highly resistant to chemo- or radiotherapy [<xref ref-type="bibr" rid="B1">1</xref>], has a 5-year survival rate of only 4% and ranks as fourth leading cause of cancer death [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. One reason contributing to this high mortality is cancer cachexia, defined as an unintended weight loss of more than 10% in 6&#x02009;months, which is present in more than 80% of pancreatic cancer patients [<xref ref-type="bibr" rid="B5">5</xref>]. Cancer cachexia is also a predictor for reduced quality of life, increased mortality, and poor response to therapy [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B10">10</xref>]. A deficiency of L-Carnitine has been proposed to be an underlying cause of cancer cachexia [<xref ref-type="bibr" rid="B11">11</xref>] and tumor associated fatigue [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. Although L-Carnitine can be generated via endogenous conversion from lysine and methionine, 75% of the required levels are provided from food sources. In vitro studies in human tumor cell lines have shown a positive effect of L-Carnitine regarding the inhibition of apoptosis and DNA-damage [<xref ref-type="bibr" rid="B15">15</xref>]. On the other hand, L-Carnitine is well known for its potential to modulate the inflammatory response mechanisms, which is known to play the predominant role in the generation of cancer cachexia, especially in pancreatic tumor patients [<xref ref-type="bibr" rid="B16">16</xref>]. We therefore conducted a multicentre trial to investigate the role of oral L-Carnitine supplementation on cancer cachexia in pancreatic cancer (CARPAN).</p></sec><sec sec-type="methods"><title>Methods</title><p>Patients from 4 participating tertiary referral centers were considered eligible for inclusion when they had histologically proven, advanced and irresectable adenocarcinoma of the pancreas (UICC Stage IV), had a Karnofsky performance status of &#x0003e;60 and declared their written informed consent to participate. The CARPAN protocol was approved by the ethics committee of Greifswald University (Reg.Nr.IIIUV73/05) and registered at clinical-trials.gov (NCT01330823) and under ISRCTN83465351. Patients were recruited regardless of concomitant or scheduled chemotherapy. Exclusion criteria were liver failure, a second malignancy, treatment with omega-3-fatty acids and the presence of a mental disorder precluding informed consent. From May 2006 until October 2009 a total of 152 patients were screened and 72 enrolled in the study (Figure <xref ref-type="fig" rid="F1">1</xref>). Reasons for non-enrollment were mostly due to poor performance status or withheld consent. Patients were randomized (sequential series of 4 per block, sealed envelopes, computer generated randomization code) to receive either an oral liquid formulation of L-Carnitine (4&#x02009;g/d, obtained from Lonza, Basel, CH) or identically formulated placebo with follow up visits at 6 and 12&#x02009;weeks after entry. Compliance was tested by determining serum L-Carnitine levels by Tandem-Mass-Spectrometry (normal range between 40&#x02013;60&#x02009;&#x003bc;mol/l) (ABI 2000, Perkin-Elmer, Turku, SF) [<xref ref-type="bibr" rid="B17">17</xref>]. L-Carnitine deficiency is generally believed to occur below 30&#x02009;&#x003bc;mol/l, albeit data on functional relevance are controversially discussed [<xref ref-type="bibr" rid="B18">18</xref>]. At every study visit adverse events and body mass index (BMI) were recorded and bioelectrical impedance analysis (BIA-Nutrigard-M, Darmstadt, Germany) was used to determine body composition [<xref ref-type="bibr" rid="B19">19</xref>]. For evaluation of quality of life we used the EORTC-QLQ-C30 questionnaire with a pancreatic cancer specific module PAN26 [<xref ref-type="bibr" rid="B20">20</xref>] and for fatigue the Brief Fatigue Inventory (BFI) questionnaire [<xref ref-type="bibr" rid="B21">21</xref>]. Survival time in days was calculated from time of diagnosis to death. Sample size calculation was based on previous studies investigating the effect of L-Carnitine on inflammatory markers [<xref ref-type="bibr" rid="B22">22</xref>], with TNF&#x003b1; level differences as primary endpoint, and resulted in a recruitment goal of 90 patients (45 per treatment arm) for a statistical power of 90% with an error probability of &#x0003c;5%. After a prescheduled interim analysis for sample size recalculation of 72 blinded datasets showed a wide variation of the standard errors for inflammatory markers a recruitment of 554 patients (277 per group) would have been necessary. Since this goal was unattainable the study was closed after enrolment of 72 patients and the data were unblinded for statistical analysis.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Flow chart of the trial.</p></caption><graphic xlink:href="1475-2891-11-52-1"/></fig><p>Data are presented as means&#x02009;&#x000b1;&#x02009;SEM and 95% confidence intervals where appropriate. Statistical analysis for intention-to-treat and per-protocol analysis was done by Student&#x02019;s&#x02009;<italic>t</italic> test and Pearson's chi-square test for parametric and Mann&#x02013;Whitney-U-Test for non-parametric analysis. Quality of life data were analyzed using ANOVA. Results were considered significant when p was &#x0003c;0,05.</p></sec><sec sec-type="results"><title>Results</title><p>Patient characteristics are given in Table <xref ref-type="table" rid="T1">1</xref> and showed no statistical difference between both groups at enrolment.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Characteristics of the study population (n&#x02009;=&#x02009;72) at baseline visit of the study (mean&#x02009;&#x000b1;&#x02009;SEM)</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th colspan="2" align="left"><bold>Parameter</bold></th><th align="left"><bold>L-Carnitine (n&#x02009;=&#x02009;38)</bold></th><th align="left"><bold>Placebo (n&#x02009;=&#x02009;34)</bold></th></tr></thead><tbody valign="top"><tr><td rowspan="2" align="left" valign="bottom">gender<hr/></td><td align="left" valign="bottom">male<hr/></td><td align="left" valign="bottom">20 (52.6%)<hr/></td><td align="left" valign="bottom">23 (67.6%)<hr/></td></tr><tr><td align="left" valign="bottom">female<hr/></td><td align="left" valign="bottom">18 (47.4%)<hr/></td><td align="left" valign="bottom">11 (32.4%)<hr/></td></tr><tr><td colspan="2" align="left" valign="bottom">mean age<hr/></td><td align="left" valign="bottom">64.4&#x02009;&#x000b1;&#x02009;1.67<hr/></td><td align="left" valign="bottom">64.4&#x02009;&#x000b1;&#x02009;1.65<hr/></td></tr><tr><td colspan="2" align="left" valign="bottom">Karnofsky performance status<hr/></td><td align="left" valign="bottom">76.8&#x02009;&#x000b1;&#x02009;1.87<hr/></td><td align="left" valign="bottom">80.0&#x02009;&#x000b1;&#x02009;2.16<hr/></td></tr><tr><td colspan="4" align="left" valign="bottom"><bold>Nutritional Status</bold><hr/></td></tr><tr><td colspan="2" align="left" valign="bottom">normal BMI (kg/m&#x000b2;)<hr/></td><td align="left" valign="bottom">28.0&#x02009;&#x000b1;&#x02009;1.01<hr/></td><td align="left" valign="bottom">30.1&#x02009;&#x000b1;&#x02009;0.84<hr/></td></tr><tr><td colspan="2" align="left" valign="bottom">baseline visit BMI (kg/m&#x000b2;)<hr/></td><td align="left" valign="bottom">24.7&#x02009;&#x000b1;&#x02009;0.65<hr/></td><td align="left" valign="bottom">24.9&#x02009;&#x000b1;&#x02009;0.89<hr/></td></tr><tr><td colspan="2" align="left" valign="bottom">Phase angle (&#x000b0;)<hr/></td><td align="left" valign="bottom">4.4&#x02009;&#x000b1;&#x02009;0.16<hr/></td><td align="left" valign="bottom">4.4&#x02009;&#x000b1;&#x02009;0.17<hr/></td></tr><tr><td rowspan="2" align="left" valign="bottom">Weight loss*<hr/></td><td align="left" valign="bottom">present<hr/></td><td align="left" valign="bottom">34 (89.5%)<hr/></td><td align="left" valign="bottom">31 (91.2%)<hr/></td></tr><tr><td align="left" valign="bottom">absent<hr/></td><td align="left" valign="bottom">4 (10.5%)<hr/></td><td align="left" valign="bottom">3 (8.8%)<hr/></td></tr><tr><td colspan="2" align="left" valign="bottom">meanweight loss (kg)*<hr/></td><td align="left" valign="bottom">11.4&#x02009;&#x000b1;&#x02009;1.28<hr/></td><td align="left" valign="bottom">12.3&#x02009;&#x000b1;&#x02009;1.56<hr/></td></tr><tr><td rowspan="2" align="left" valign="bottom">Nutritional support<hr/></td><td align="left" valign="bottom">none<hr/></td><td align="left" valign="bottom">20 (52.6%)<hr/></td><td align="left" valign="bottom">21 (61.8%)<hr/></td></tr><tr><td align="left" valign="bottom">oral<hr/></td><td align="left" valign="bottom">14 (36.8%)<hr/></td><td align="left" valign="bottom">9 (26.5%)<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Parenteral nutrition<hr/></td><td align="left" valign="bottom">4 (10.5%)<hr/></td><td align="left" valign="bottom">4 (11.7%)<hr/></td></tr><tr><td colspan="2" align="left" valign="bottom">ECM/BCM index **<hr/></td><td align="left" valign="bottom">1.5&#x02009;&#x000b1;&#x02009;0.11<hr/></td><td align="left" valign="bottom">1.4&#x02009;&#x000b1;&#x02009;0<hr/></td></tr><tr><td colspan="2" align="left" valign="bottom">Cell percentage (%)<hr/></td><td align="left" valign="bottom">41.8&#x02009;&#x000b1;&#x02009;1.22<hr/></td><td align="left" valign="bottom">42.70&#x02009;&#x000b1;&#x02009;1.21<hr/></td></tr><tr><td colspan="4" align="left" valign="bottom">chemotherapy (n) 35 (92%) 30 (88%)<hr/></td></tr><tr><td colspan="4" align="left" valign="bottom"><bold>Laboratory values</bold><hr/></td></tr><tr><td colspan="2" align="left" valign="bottom">L-Carnitine level (&#x003bc;mol/l)<hr/></td><td align="left" valign="bottom">25.3&#x02009;&#x000b1;&#x02009;2.29<hr/></td><td align="left" valign="bottom">24. 8&#x02009;&#x000b1;&#x02009;2.11<hr/></td></tr><tr><td colspan="2" align="left" valign="bottom">Albumine (g/l)<hr/></td><td align="left" valign="bottom">33.8&#x02009;&#x000b1;&#x02009;1.09<hr/></td><td align="left" valign="bottom">33.7&#x02009;&#x000b1;&#x02009;1.20<hr/></td></tr><tr><td colspan="2" align="left" valign="bottom">CRP (mg/l)<hr/></td><td align="left" valign="bottom">31.3&#x02009;&#x000b1;&#x02009;6.55<hr/></td><td align="left" valign="bottom">45.5&#x02009;&#x000b1;&#x02009;10.39<hr/></td></tr><tr><td colspan="2" align="left" valign="bottom">Leucocytes (Gpt/l)<hr/></td><td align="left" valign="bottom">8.3&#x02009;&#x000b1;&#x02009;0.83<hr/></td><td align="left" valign="bottom">6.9&#x02009;&#x000b1;&#x02009;0.46<hr/></td></tr><tr><td colspan="2" align="left">CA 19&#x02013;9 (U/ml)</td><td align="left">14,095&#x02009;&#x000b1;&#x02009;32,572</td><td align="left">18,345&#x02009;&#x000b1;&#x02009;35,950</td></tr></tbody></table><table-wrap-foot><p>No statistically significant differences were observed between L-Carnitine and placebo group.</p><p>*weight loss during the last 6&#x02009;month.</p><p>**ECM/BCM-Index, Extra-Cellular-Mass/Body-Cell-Mass-Index.</p></table-wrap-foot></table-wrap><p>At entry 88% of patients in the placebo and 92% of patients in the L-Carnitine group received chemotherapy. There was no statistically significant difference between both groups (p&#x02009;&#x0003c;&#x02009;0,05). 90% of the patients reported a weight loss of &#x0003e;10% during the previous 6&#x02009;month. This observation is in line with previous reports on cancer cachexia [<xref ref-type="bibr" rid="B5">5</xref>]. 26 patients completed the entire follow up period and premature drop-out was due to death (n&#x02009;=&#x02009;11), deteriorating health (n&#x02009;=&#x02009;9), nausea (n&#x02009;=&#x02009;8), excessive demand (n&#x02009;=&#x02009;5), diarrhea (n&#x02009;=&#x02009;2) or miscellaneous symptoms (n&#x02009;=&#x02009;7). Drop out rates and reasons were not different between both treatment arms. Oral supplementation of L-Carnitine substantially increased L-Carnitine serum plasma levels up to 60% of the basic value at week 6 (p&#x02009;&#x0003c;&#x02009;0,009) in the L-Carnitine group (Figure <xref ref-type="fig" rid="F2">2</xref>), while a constant decline of L-Carnitine plasma levels was evident during the observation period in the placebo group. This might be related to tumor effects and / or due to concomitant chemotherapy. L-Carnitine supplementation was well tolerated. Side effects did not differ significantly in comparison with placebo group (predominantly nausea, vomiting, and diarrhoea) and, whenever they occurred, may have been caused by concomitant chemotherapy.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Reasons for discontinued convention of the study patients.</bold> Reasons for discontinued convention of the study patients.</p></caption><graphic xlink:href="1475-2891-11-52-2"/></fig><p>Patients on L-Carnitine treatment gained weight (BMI increase of 3.4%&#x02009;&#x000b1;&#x02009;1.35)whereas patients on placebo did not (BMI reduction of 1.5%&#x02009;&#x000b1;&#x02009;1.4, p&#x02009;&#x0003c;&#x02009;0.018). After 12&#x02009;weeks of therapy the difference amounted to 4.9%&#x02009;&#x000b1;&#x02009;1.9 (Figure <xref ref-type="fig" rid="F3">3</xref>) between groups. BIA revealed that this improvement was due to increases in body cell mass (BCM, p&#x02009;&#x0003c;&#x02009;0,013) and body fat (BF, p&#x02009;&#x0003c;&#x02009;0,041). CRP, albumin, leukocyte count and CA19-9 remained unaffected (data not shown). Regarding quality of life (EORTC-QLQ-C30/PAN26) the only significant changes were improvement in cognitive function (at enrolment 81,0&#x02009;&#x000b1;&#x02009;21,5 in L-Carnitine group, 86,1&#x02009;&#x000b1;&#x02009;17,2 in placebo group; after 6&#x02009;-weeks L- Carnitine group 0,30 versus &#x02212;0,13 in the placebo group, p&#x02009;&#x0003c;&#x02009;0,034), improvement of global health s\tatus (at enrolment 53,6&#x02009;&#x000b1;&#x02009;19,5 in L-Carnitine group, 65,3&#x02009;&#x000b1;&#x02009;17,7 in placebo group; after 12 weeks L- Carnitine group 0,76 versus &#x02212;0,32 in the placebo group, p&#x02009;&#x0003c;&#x02009;0,041) and reduction in gastrointestinal symptoms (at enrolment 29,8&#x02009;&#x000b1;&#x02009;32,1 in L-Carnitine group, 19,4&#x02009;&#x000b1;&#x02009;24,5; in the placebo group; after 12&#x02009;weeks&#x02009;L-Carnitine group &#x02212;0,35 versus 0,78 in the placebo group; p&#x02009;&#x0003c;&#x02009;0,033). Differences in fatigue (moderate/severe, &#x0003e;4 on BFI), present in 28,6% of L-Carnitine patients versus 41,7% in the placebogroup,were not statistically significant, nor was the survival benefit (Figure <xref ref-type="fig" rid="F2">2</xref>, median 519&#x02009;&#x000b1;&#x02009;50d versus 399&#x02009;&#x000b1;&#x02009;43d with placebo), and the reduction in length of hospital stay (36&#x02009;&#x000b1;&#x02009;4d versus 41&#x02009;&#x000b1;&#x02009;9d with placebo).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Relevant nutritional parameters and survival.</bold> Relevant nutritional parameters (means&#x02009;&#x000b1;&#x02009;SEM) and survival in days in the L-Carnitine treatment arm (black lines) and placebogroup (gray lines). Survival is given in days after diagnosis as Kaplan-Meier curve and body mass index (BMI), body fat, and body cell mass (BCM) aregiven as percent changes under respective treatment over 12&#x02009;weeks. Asterisks indicate statistically significant differences (p&#x02009;&#x0003c;&#x02009;0.05).</p></caption><graphic xlink:href="1475-2891-11-52-3"/></fig></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Cancer cachexia and malnutrition are associated with an increased risk of surgical complications and higher toxicity levels of chemotherapy. Quality of life and overall survival of colon cancer patients can improve under early nutritional intervention [<xref ref-type="bibr" rid="B23">23</xref>]. L-Carnitine is critical for energy generation by mitochondrial &#x000df;-oxidation and was found depleted under chemotherapy [<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>]. Its oral supplementation can normalize nutritional L-Carnitine deficiency [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>] and reduce chemotherapy related side effects [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. We therefore tested whether oral L-Carnitine supplementation has a clinical benefit in patients with advanced pancreatic cancer and found that L-Carnitine can reduce malnutrition, increase bodyweight and improve body composition.</p><p>When we planned and designed the study no persuasive data for clinical endpoints existed and we had to base the initial power calculations on inflammatory markers in humans under L-Carnitine treatment. While this study must be regarded as preliminary because inflammatory markers were found to be an unsuitable primary endpoint in our setting, the CARPAN trial provides the basis for a robust sample size calculation: a conclusive study of L-Carnitine benefits ought to enrol 148 patients in each arm to show a survival benefit with 90% power, and would need 157 patients in each arm to demonstrate an improvement in tumor fatigue. The presently available data show a benefit of L-Carnitine supplementation on body weight, body composition and some aspects of quality-of-life, even though it was underpowered to determine the statistical significance of other secondary endpoints. While the loss of significant changes in BCM at week 12 and a rapid increase in body fat between week 6 and 12 was an unexpected finding it might be explained by the underlying progressive tumor disease leading to changes in body composition, irrespective of gain of weight and due to reduced physical activity and progressive sarcopenia. Both are common findings in pancreatic tumors. In this context it is important to note, that the direct influence of L-Carnitine on tumor growth has not been measured in this study and is beyond the scope of this work. Future studies are needed to address this question as only recently L-Carnitine has been reported to modify apoptosis and DNA-damage in tumor cell lines of the brain via CPT-1&#x02009;C [<xref ref-type="bibr" rid="B15">15</xref>].</p><p>The CARPAN trial could suggest that the clinical benefit of an inexpensive and very well tolerated oral L-Carnitine supplementation may reach the clinical benefit level previously shown for palliative Gemcitabine chemotherapy [<xref ref-type="bibr" rid="B31">31</xref>] in pancreatic cancer patients.</p></sec><sec><title>Abbreviations</title><p>BIA, Bioelectrical impedance analysis; BF, Body fat; BFI, Brief fatigue inventory; BMI, Body mass index; BCM, Body cell mass; CPT, Carnitine palmitoyltransferase; CRP, C-reactive protein; ECM, Extra cellular mass; SEM, Standard error of the mean; TNF&#x003b1;, Tumor nekrose faktor &#x003b1;.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors&#x02019; contribution</title><p>All authors of the study substantially contributed to conception, design, acquisition and analysis of data and interpretation of the study. KK, MK, MML, UG, and PH designed research, SG, JM, PS, KS, JS, HKJ, AA, CN, PM and MP conducted research, JR, MF, HV and CDH provided essential materials, CM, GE, EW, YSF and TK analysed data, KK, MK and MML wrote paper, KK, MK and MML had primary responsibility for final content. All authors read and approved the final manuscript and disclose any financial or personal relationships.</p></sec></body><back><sec><title>Acknowledgement</title><p>This study was supported by the Alfried-Krupp-von-Bohlen-und-Hahlbach-Foundation (Graduate Schools Tumour Biology and Free Radical Biology), the Deutsche Krebshilfe/ Dr. Mildred-Scheel-Stiftung (109102), the Deutsche Forschungsgemeinschaft (DFGgRK840-E3/E4, MA 4115/1-2/3, NI 1297/1-1), the Federal Ministry of Education and Research (BMBFgANI-MED 03152061A and BMBF 0314107) and the European Union (EU-FP-7: EPC-TM and EU-FP7-REGPOT-2010-1). KK and SG both received a Gerhard-Domagk-Stipendium of Greifswald University Medicine made possible through unrestricted educational grants from Medinal GmbH, Greven, Germany, Fresenius Kabi Germany GmbH Bad Homburg, Germany and Nutricia GmbH, Erlangen, Germany. L-Carnitine bulk compound was kindly provided by Lonza Ltd., Basel, Switzerland.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Rocha-Lima</surname><given-names>CM</given-names></name><article-title>New directions in the management of advanced pancreatic cancer: a review</article-title><source>Anticancer Drugs</source><year>2008</year><volume>19</volume><fpage>435</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1097/CAD.0b013e3282fc9d11</pub-id><pub-id pub-id-type="pmid">18418211</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Greenlee</surname><given-names>RT</given-names></name><name><surname>Hill-Harmon</surname><given-names>MB</given-names></name><name><surname>Murray</surname><given-names>T</given-names></name><name><surname>Thun</surname><given-names>M</given-names></name><article-title>Cancer statistics, 2001</article-title><source>CA Cancer J Clin</source><year>2001</year><volume>51</volume><fpage>15</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.3322/canjclin.51.1.15</pub-id><pub-id pub-id-type="pmid">11577478</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>DiMagno</surname><given-names>EP</given-names></name><name><surname>Reber</surname><given-names>HA</given-names></name><name><surname>Tempero</surname><given-names>MA</given-names></name><article-title>AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma</article-title><source>Americangastroenterological Association. gastroenterology</source><year>1999</year><volume>117</volume><fpage>1464</fpage><lpage>1484</lpage></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Neoptolemos</surname><given-names>JP</given-names></name><name><surname>Stocken</surname><given-names>DD</given-names></name><name><surname>Bassi</surname><given-names>C</given-names></name><name><surname>Ghaneh</surname><given-names>P</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Goldstein</surname><given-names>D</given-names></name><name><surname>Padbury</surname><given-names>R</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name><name><surname>Mariette</surname><given-names>C</given-names></name><etal/><article-title>Adjuvant chemotherapy with fluorouracil plus folinic acid vsgemcitabine following pancreatic cancer resection: a randomized controlled trial</article-title><source>JAMA</source><year>2010</year><volume>304</volume><fpage>1073</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1001/jama.2010.1275</pub-id><pub-id pub-id-type="pmid">20823433</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Bachmann</surname><given-names>J</given-names></name><name><surname>Ketterer</surname><given-names>K</given-names></name><name><surname>Marsch</surname><given-names>C</given-names></name><name><surname>Fechtner</surname><given-names>K</given-names></name><name><surname>Krakowski-Roosen</surname><given-names>H</given-names></name><name><surname>B&#x000fc;chler</surname><given-names>MW</given-names></name><name><surname>Friess</surname><given-names>H</given-names></name><name><surname>Martignoni</surname><given-names>ME</given-names></name><article-title>Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function</article-title><source>BMC Cancer</source><year>2009</year><volume>9</volume><fpage>255</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-9-255</pub-id><pub-id pub-id-type="pmid">19635171</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Pelzer</surname><given-names>U</given-names></name><name><surname>Arnold</surname><given-names>D</given-names></name><name><surname>Govercin</surname><given-names>M</given-names></name><name><surname>Stieler</surname><given-names>J</given-names></name><name><surname>Doerken</surname><given-names>B</given-names></name><name><surname>Riess</surname><given-names>H</given-names></name><name><surname>Oettle</surname><given-names>H</given-names></name><article-title>Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study</article-title><source>BMC Cancer</source><year>2010</year><volume>10</volume><fpage>86</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-10-86</pub-id><pub-id pub-id-type="pmid">20214798</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Uomog</surname></name><name><surname>Gallucci</surname><given-names>F</given-names></name><name><surname>Rabitti</surname><given-names>PG</given-names></name><article-title>Anorexia-cachexia syndrome in pancreatic cancer: recent development in research and management</article-title><source>JOP</source><year>2006</year><volume>7</volume><fpage>157</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">16525199</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Ockenga</surname><given-names>J</given-names></name><name><surname>Valentini</surname><given-names>L</given-names></name><article-title>Review article: anorexia and cachexia in gastrointestinal cancer</article-title><source>Aliment Pharmacol Ther</source><year>2005</year><volume>22</volume><fpage>583</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2005.02628.x</pub-id><pub-id pub-id-type="pmid">16181298</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Bozzetti</surname><given-names>F</given-names></name><article-title>Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients</article-title><source>Support Care Cancer</source><year>2009</year><volume>17</volume><fpage>279</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1007/s00520-008-0476-3</pub-id><pub-id pub-id-type="pmid">18581148</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Cohen</surname><given-names>SJ</given-names></name><name><surname>Pinoverw</surname><given-names>H</given-names></name><name><surname>Watson</surname><given-names>JC</given-names></name><name><surname>Meropol</surname><given-names>NJ</given-names></name><article-title>Pancreatic cancer</article-title><source>Curr Treat Options Oncol</source><year>2000</year><volume>1</volume><fpage>375</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1007/s11864-000-0065-2</pub-id><pub-id pub-id-type="pmid">12057145</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Malaguarnera</surname><given-names>M</given-names></name><name><surname>Risino</surname><given-names>C</given-names></name><name><surname>Gargante</surname><given-names>MP</given-names></name><name><surname>Tomasello</surname><given-names>AV</given-names></name><name><surname>Costanzo</surname><given-names>M</given-names></name><name><surname>Cannizzaro</surname><given-names>MA</given-names></name><name><surname>Costanzo</surname><given-names>M</given-names></name><name><surname>Cannizzaro</surname><given-names>MA</given-names></name><article-title>Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia</article-title><source>World Jgastroenterol</source><year>2006</year><volume>12</volume><fpage>4541</fpage><lpage>4545</lpage></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Graziano</surname><given-names>F</given-names></name><name><surname>Bisonni</surname><given-names>R</given-names></name><name><surname>Catalano</surname><given-names>V</given-names></name><name><surname>Silva</surname><given-names>R</given-names></name><name><surname>Rovidati</surname><given-names>S</given-names></name><name><surname>Mencarini</surname><given-names>E</given-names></name><name><surname>Ferraro</surname><given-names>B</given-names></name><name><surname>Canestrari</surname><given-names>F</given-names></name><name><surname>Baldelli</surname><given-names>AM</given-names></name><name><surname>Deg</surname><given-names>A</given-names></name><etal/><article-title>Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients</article-title><source>Br J Cancer</source><year>2002</year><volume>86</volume><fpage>1854</fpage><lpage>1857</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6600413</pub-id><pub-id pub-id-type="pmid">12085175</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Stone</surname><given-names>P</given-names></name><name><surname>Richardson</surname><given-names>A</given-names></name><name><surname>Ream</surname><given-names>E</given-names></name><name><surname>Smith</surname><given-names>AG</given-names></name><name><surname>Kerr</surname><given-names>DJ</given-names></name><name><surname>Kearney</surname><given-names>N</given-names></name><article-title>Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey</article-title><source>Cancer Fatigue Forum. Ann Oncol</source><year>2000</year><volume>11</volume><fpage>971</fpage><lpage>975</lpage></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Schwartz</surname><given-names>AL</given-names></name><name><surname>Nail</surname><given-names>LM</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Meek</surname><given-names>P</given-names></name><name><surname>Barsevick</surname><given-names>AM</given-names></name><name><surname>King</surname><given-names>ME</given-names></name><name><surname>Jones</surname><given-names>LS</given-names></name><article-title>Fatigue patterns observed in patients receiving chemotherapy and radiotherapy</article-title><source>Cancer Invest</source><year>2000</year><volume>18</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.3109/07357900009023057</pub-id><pub-id pub-id-type="pmid">10701362</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Zaugg</surname><given-names>K</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Reilly</surname><given-names>PT</given-names></name><name><surname>Kannan</surname><given-names>K</given-names></name><name><surname>Kiarash</surname><given-names>R</given-names></name><name><surname>Mason</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name><name><surname>Sawyer</surname><given-names>SK</given-names></name><name><surname>Fuerth</surname><given-names>B</given-names></name><name><surname>Faubert</surname><given-names>B</given-names></name><etal/><article-title>Carnitine palmitoyltransferase 1&#x02009;C promotes cell survival and tumorgrowth under conditions of metabolic stress</article-title><source>Genes Dev</source><year>2011</year><volume>25</volume><fpage>1041</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1101/gad.1987211</pub-id><pub-id pub-id-type="pmid">21576264</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>ZQ</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>JP</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><article-title>L-Carnitine ameliorates cancer cachexia in mice by regulating the expression and activity of carnitine palmityl transferase</article-title><source>Cancer Biol Ther</source><year>2011</year><volume>12</volume><fpage>125</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.4161/cbt.12.2.15717</pub-id><pub-id pub-id-type="pmid">21532335</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Kodo</surname><given-names>N</given-names></name><name><surname>Millington</surname><given-names>DS</given-names></name><name><surname>Norwood</surname><given-names>DL</given-names></name><name><surname>Roe</surname><given-names>CR</given-names></name><article-title>Quantitative assay of free and total carnitine using tandem mass spectrometry</article-title><source>Clin Chim Acta</source><year>1990</year><volume>186</volume><fpage>383</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1016/0009-8981(90)90324-L</pub-id><pub-id pub-id-type="pmid">2311263</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Rebouche</surname><given-names>CJ</given-names></name><article-title>Carnitine function and requirements during the life cycle</article-title><source>FASEB J</source><year>1992</year><volume>6</volume><fpage>3379</fpage><lpage>3386</lpage><pub-id pub-id-type="pmid">1464372</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Bosy-Westphal</surname><given-names>A</given-names></name><name><surname>Danielzik</surname><given-names>S</given-names></name><name><surname>Dorhofer</surname><given-names>RP</given-names></name><name><surname>Later</surname><given-names>W</given-names></name><name><surname>Wiese</surname><given-names>S</given-names></name><name><surname>Muller</surname><given-names>MJ</given-names></name><article-title>Phase angle from bioelectrical impedance analysis: population reference values by age, sex, and body mass index</article-title><source>JPEN J Parenter Enteral Nutr</source><year>2006</year><volume>30</volume><fpage>309</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1177/0148607106030004309</pub-id><pub-id pub-id-type="pmid">16804128</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Fitzsimmons</surname><given-names>D</given-names></name><name><surname>Johnson</surname><given-names>CD</given-names></name><name><surname>George</surname><given-names>S</given-names></name><name><surname>Payne</surname><given-names>S</given-names></name><name><surname>Sandberg</surname><given-names>AA</given-names></name><name><surname>Bassi</surname><given-names>C</given-names></name><name><surname>Beger</surname><given-names>HG</given-names></name><name><surname>Birk</surname><given-names>D</given-names></name><name><surname>Buchler</surname><given-names>MW</given-names></name><name><surname>Dervenis</surname><given-names>C</given-names></name><etal/><article-title>Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study group on Quality of Life</article-title><source>Eur J Cancer</source><year>1999</year><volume>35</volume><fpage>939</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(99)00047-7</pub-id><pub-id pub-id-type="pmid">10533475</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Radbruch</surname><given-names>L</given-names></name><name><surname>Sabatowski</surname><given-names>R</given-names></name><name><surname>Elsner</surname><given-names>F</given-names></name><name><surname>Everts</surname><given-names>J</given-names></name><name><surname>Mendoza</surname><given-names>T</given-names></name><name><surname>Cleeland</surname><given-names>C</given-names></name><article-title>Validation of thegerman version of the brief fatigue inventory</article-title><source>J Pain Symptom Manage</source><year>2003</year><volume>25</volume><fpage>449</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1016/S0885-3924(03)00073-3</pub-id><pub-id pub-id-type="pmid">12727043</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Grazig</surname><given-names>G</given-names></name><name><surname>Meriggioli</surname><given-names>M</given-names></name><article-title>Can the treatment with L-carnitine improve the inflammation in chronic hemo dialysis patients?</article-title><source>G Ital Nefrol</source><year>2004</year><volume>21</volume><issue>Suppl 30</issue><fpage>S204</fpage><lpage>S207</lpage><pub-id pub-id-type="pmid">15750986</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Nitenbergg</surname></name><name><surname>Raynard</surname><given-names>B</given-names></name><article-title>Nutritional support of the cancer patient: issues and dilemmas</article-title><source>Crit Rev Oncol Hematol</source><year>2000</year><volume>34</volume><fpage>137</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/S1040-8428(00)00048-2</pub-id><pub-id pub-id-type="pmid">10838261</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Dodsonw</surname><given-names>L</given-names></name><name><surname>Sachan</surname><given-names>DS</given-names></name><name><surname>Krauss</surname><given-names>S</given-names></name><name><surname>Hanna</surname><given-names>W</given-names></name><article-title>Alterations of serum and urinary carnitine profiles in cancer patients: hypothesis of possible significance</article-title><source>J Am Coll Nutr</source><year>1989</year><volume>8</volume><fpage>133</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">2708729</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Mancinelli</surname><given-names>A</given-names></name><name><surname>D'Iddio</surname><given-names>S</given-names></name><name><surname>Bisonni</surname><given-names>R</given-names></name><name><surname>Graziano</surname><given-names>F</given-names></name><name><surname>Lippe</surname><given-names>P</given-names></name><name><surname>Calvani</surname><given-names>M</given-names></name><article-title>Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment</article-title><source>Cancer Chemother Pharmacol</source><year>2007</year><volume>60</volume><fpage>19</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1007/s00280-006-0341-3</pub-id><pub-id pub-id-type="pmid">16988826</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Lancaster</surname><given-names>CS</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Franke</surname><given-names>RM</given-names></name><name><surname>Filipski</surname><given-names>KK</given-names></name><name><surname>Orwick</surname><given-names>SJ</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zuo</surname><given-names>Z</given-names></name><name><surname>Loosw</surname><given-names>J</given-names></name><name><surname>Sparreboom</surname><given-names>A</given-names></name><article-title>Cisplatin-induced down regulation of OCTN2 affects carnitine wasting</article-title><source>Clin Cancer Res</source><year>2010</year><volume>16</volume><fpage>4789</fpage><lpage>4799</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-1239</pub-id><pub-id pub-id-type="pmid">20858838</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Lebrun</surname><given-names>C</given-names></name><name><surname>Alchaar</surname><given-names>H</given-names></name><name><surname>Candito</surname><given-names>M</given-names></name><name><surname>Bourg</surname><given-names>V</given-names></name><name><surname>Chatel</surname><given-names>M</given-names></name><article-title>Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue</article-title><source>Mult Scler</source><year>2006</year><volume>12</volume><fpage>321</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1191/135248506ms1275oa</pub-id><pub-id pub-id-type="pmid">16764345</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Cruciani</surname><given-names>RA</given-names></name><name><surname>Dvorkin</surname><given-names>E</given-names></name><name><surname>Homel</surname><given-names>P</given-names></name><name><surname>Culliney</surname><given-names>B</given-names></name><name><surname>Malamud</surname><given-names>S</given-names></name><name><surname>Lapin</surname><given-names>J</given-names></name><name><surname>Portenoy</surname><given-names>RK</given-names></name><name><surname>Esteban-Cruciani</surname><given-names>N</given-names></name><article-title>L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study</article-title><source>J Pain Symptom Manage</source><year>2009</year><volume>37</volume><fpage>622</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1016/j.jpainsymman.2008.03.021</pub-id><pub-id pub-id-type="pmid">18809275</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Pisano</surname><given-names>C</given-names></name><name><surname>Vesci</surname><given-names>L</given-names></name><name><surname>Milazzo</surname><given-names>FM</given-names></name><name><surname>Guglielmi</surname><given-names>MB</given-names></name><name><surname>Fodera</surname><given-names>R</given-names></name><name><surname>Barbarino</surname><given-names>M</given-names></name><name><surname>D'Incalci</surname><given-names>M</given-names></name><name><surname>Zucchetti</surname><given-names>M</given-names></name><name><surname>Petrangolini</surname><given-names>G</given-names></name><name><surname>Tortoreto</surname><given-names>M</given-names></name><etal/><article-title>Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine</article-title><source>Clin Cancer Res</source><year>2010</year><volume>16</volume><fpage>3944</fpage><lpage>3953</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-0964</pub-id><pub-id pub-id-type="pmid">20562210</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Haschke</surname><given-names>M</given-names></name><name><surname>Vitins</surname><given-names>T</given-names></name><name><surname>Lude</surname><given-names>S</given-names></name><name><surname>Todesco</surname><given-names>L</given-names></name><name><surname>Novakova</surname><given-names>K</given-names></name><name><surname>Herrmann</surname><given-names>R</given-names></name><name><surname>Krahenbuhl</surname><given-names>S</given-names></name><article-title>Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based anti neo plastic drugs</article-title><source>Nephrol Dial Transplant</source><year>2010</year><volume>25</volume><fpage>426</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfp456</pub-id><pub-id pub-id-type="pmid">19736245</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Burris</surname><given-names>HA</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Andersen</surname><given-names>J</given-names></name><name><surname>Green</surname><given-names>MR</given-names></name><name><surname>Rothenberg</surname><given-names>ML</given-names></name><name><surname>Modiano</surname><given-names>MR</given-names></name><name><surname>Cripps</surname><given-names>MC</given-names></name><name><surname>Portenoy</surname><given-names>RK</given-names></name><name><surname>Storniolo</surname><given-names>AM</given-names></name><name><surname>Tarassoff</surname><given-names>P</given-names></name><etal/><article-title>Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer a randomized trial</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><fpage>2403</fpage><lpage>2413</lpage><pub-id pub-id-type="pmid">9196156</pub-id></mixed-citation></ref></ref-list></back></article>